首页 > 最新文献

Rheumatology and immunology research最新文献

英文 中文
Nitazoxanide alleviates CFA-induced rheumatoid arthritis in Wistar rats by modulating the STAT-3 and NF-κB pathways. 硝唑尼特通过调节 STAT-3 和 NF-κB 通路缓解 CFA 诱导的 Wistar 大鼠类风湿性关节炎。
Pub Date : 2025-04-02 eCollection Date: 2025-03-01 DOI: 10.1515/rir-2025-0004
Pradyuman Prajapati, Gaurav Doshi

Background and objective: Rheumatoid arthritis (RA) is a chronic autoimmune condition characterized by joint pain and inflammation. RA involves elevated expression of nuclear factor kappa B (NF-κB), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), which drive synovial inflammation and joint destruction primarily through the STAT-3 signalling pathway. Nitazoxanide (NTZ) has been shown in previous studies to inhibit the signalling of STAT-3.

Methods: This study evaluated the anti-arthritic effects of NTZ in a rat model of complete Freund's adjuvant (CFA) induced arthritis. NTZ was administered orally at doses of 400, 200, and 100 mg/kg over 28 days. Various parameters, including changes in paw swelling, body weight, arthritic index, haematological measurements, levels of inflammatory cytokines, and histopathological analysis, were monitored.

Results: NTZ treatment significantly improved body weight and reduced paw swelling, edema, and the arthritic index in CFA-induced arthritic rats. The treatment also decreased white blood cell counts while increasing red blood cell and haemoglobin levels. NTZ effectively modulated inflammatory cytokine levels and showed improvement in the histopathology of the ankle joints.

Conclusion: NTZ exhibited significant anti-arthritic activity through the inhibition of the STAT-3 and NF-κB pathways, emphasizing its potential as a therapeutic option for rheumatoid arthritis.

背景和目的:类风湿性关节炎(RA)是一种以关节疼痛和炎症为特征的慢性自身免疫性疾病。RA 涉及核因子卡巴 B(NF-κB)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的表达升高,它们主要通过 STAT-3 信号通路驱动滑膜炎症和关节破坏。以往的研究表明,硝唑尼特(NTZ)可抑制 STAT-3 的信号传导:本研究评估了 NTZ 在大鼠完全弗氏佐剂(CFA)诱导的关节炎模型中的抗关节炎作用。NTZ的口服剂量分别为400、200和100毫克/千克,持续28天。对各种参数进行了监测,包括爪肿、体重、关节炎指数、血液学测量、炎症细胞因子水平和组织病理学分析的变化:结果:NTZ治疗可明显改善CFA诱导的关节炎大鼠的体重,减轻爪肿、水肿和关节炎指数。治疗还降低了白细胞计数,同时提高了红细胞和血红蛋白水平。NTZ能有效调节炎症细胞因子水平,并改善踝关节的组织病理学:结论:NTZ通过抑制STAT-3和NF-κB通路表现出明显的抗关节炎活性,强调了其作为类风湿关节炎治疗选择的潜力。
{"title":"Nitazoxanide alleviates CFA-induced rheumatoid arthritis in Wistar rats by modulating the STAT-3 and NF-κB pathways.","authors":"Pradyuman Prajapati, Gaurav Doshi","doi":"10.1515/rir-2025-0004","DOIUrl":"10.1515/rir-2025-0004","url":null,"abstract":"<p><strong>Background and objective: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune condition characterized by joint pain and inflammation. RA involves elevated expression of nuclear factor kappa B (NF-κB), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), which drive synovial inflammation and joint destruction primarily through the STAT-3 signalling pathway. Nitazoxanide (NTZ) has been shown in previous studies to inhibit the signalling of STAT-3.</p><p><strong>Methods: </strong>This study evaluated the anti-arthritic effects of NTZ in a rat model of complete Freund's adjuvant (CFA) induced arthritis. NTZ was administered orally at doses of 400, 200, and 100 mg/kg over 28 days. Various parameters, including changes in paw swelling, body weight, arthritic index, haematological measurements, levels of inflammatory cytokines, and histopathological analysis, were monitored.</p><p><strong>Results: </strong>NTZ treatment significantly improved body weight and reduced paw swelling, edema, and the arthritic index in CFA-induced arthritic rats. The treatment also decreased white blood cell counts while increasing red blood cell and haemoglobin levels. NTZ effectively modulated inflammatory cytokine levels and showed improvement in the histopathology of the ankle joints.</p><p><strong>Conclusion: </strong>NTZ exhibited significant anti-arthritic activity through the inhibition of the STAT-3 and NF-κB pathways, emphasizing its potential as a therapeutic option for rheumatoid arthritis.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 1","pages":"29-41"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights into familial Mediterranean fever: Chronic disease correlations with arthralgia and current health status of patients with familial Mediterranean fever in Jordan. 家族性地中海热的见解:慢性疾病与关节痛的相关性以及约旦家族性地中海热患者目前的健康状况。
Pub Date : 2025-04-02 eCollection Date: 2025-03-01 DOI: 10.1515/rir-2025-0003
Mai I Al-Hawamdeh, Farah Othman, Safaa' Taha, Tityana Adawı, Talal Aburjaı

Background and objectives: Familial Mediterranean fever (FMF) stands as a significant challenge within Jordan's clinical practice, despite its low prevalence of 0.04% within the Jordanian population. This study aims to investigate the current status of the health status of FMF patients in Jordan while exploring any present associations between chronic diseases and the severity of their symptoms.

Methods: This is a cross-sectional descriptive survey-based study conducted during the period between 1st of March till the last of May 2023 in Jordan. The survey was distributed randomly to a group of FMF patients, Sample size was based on FMF prevalence in Jordan (0.04%); study sample (N = 67) included FMF patients in Jordan from different age groups. All results were performed through proper statistical analysis.

Results: The study includes 67 FMF patients, predominantly Jordanian and aged 18-31, revealed that 58.2% only were diagnosed through blood genetic testing. Marriages among first-degree relatives showed a 60% probability of FMF transmission compared to 10% in non-related parents (P = 0.001), leading 82.1% of participants to call for pre-marital testing. Acute symptoms included abdominal pain, fever, arthralgia, and myalgia, with hypertension being the most frequent comorbidity (14.9%) and significantly associated with myalgia and arthralgia (P < 0.05). Colchicine was the primary treatment for 89.6% of patients, with high adherence rates (90.3%).

Conclusion: Among chronic comorbidities, hypertension was associated in increasing the severity of the myalgia during attacks. The issue of misdiagnosis remains a major challenge in Jordanian clinical practice. Our findings assert the importance of future incorporation of FMF premarital testing.

背景和目的:尽管家族性地中海热(FMF)在约旦人口中的发病率较低,仅为 0.04%,但它仍是约旦临床实践中的一项重大挑战。本研究旨在调查约旦家族性地中海热患者的健康现状,同时探讨慢性疾病与其症状严重程度之间的关联:这是一项横断面描述性调查研究,于 2023 年 3 月 1 日至 5 月底在约旦进行。调查表随机发放给一组 FMF 患者,样本大小基于约旦的 FMF 患病率(0.04%);研究样本(N = 67)包括约旦不同年龄段的 FMF 患者。所有结果均通过适当的统计分析得出:研究包括 67 名 FMF 患者,主要为约旦人,年龄在 18-31 岁之间,结果显示 58.2% 的患者是通过血液基因检测确诊的。一级亲属间的婚姻显示 FMF 传播的概率为 60%,而非亲属间的概率为 10%(P = 0.001),因此 82.1%的参与者要求进行婚前检测。急性症状包括腹痛、发热、关节痛和肌痛,其中高血压是最常见的合并症(14.9%),并与肌痛和关节痛显著相关(P < 0.05)。89.6%的患者以秋水仙碱为主要治疗药物,且依从率高(90.3%):结论:在慢性并发症中,高血压会增加肌痛发作时的严重程度。误诊问题仍是约旦临床实践中的一大挑战。我们的研究结果表明,未来婚前检测FMF非常重要。
{"title":"Insights into familial Mediterranean fever: Chronic disease correlations with arthralgia and current health status of patients with familial Mediterranean fever in Jordan.","authors":"Mai I Al-Hawamdeh, Farah Othman, Safaa' Taha, Tityana Adawı, Talal Aburjaı","doi":"10.1515/rir-2025-0003","DOIUrl":"10.1515/rir-2025-0003","url":null,"abstract":"<p><strong>Background and objectives: </strong>Familial Mediterranean fever (FMF) stands as a significant challenge within Jordan's clinical practice, despite its low prevalence of 0.04% within the Jordanian population. This study aims to investigate the current status of the health status of FMF patients in Jordan while exploring any present associations between chronic diseases and the severity of their symptoms.</p><p><strong>Methods: </strong>This is a cross-sectional descriptive survey-based study conducted during the period between 1st of March till the last of May 2023 in Jordan. The survey was distributed randomly to a group of FMF patients, Sample size was based on FMF prevalence in Jordan (0.04%); study sample (<i>N</i> = 67) included FMF patients in Jordan from different age groups. All results were performed through proper statistical analysis.</p><p><strong>Results: </strong>The study includes 67 FMF patients, predominantly Jordanian and aged 18-31, revealed that 58.2% only were diagnosed through blood genetic testing. Marriages among first-degree relatives showed a 60% probability of FMF transmission compared to 10% in non-related parents (<i>P</i> = 0.001), leading 82.1% of participants to call for pre-marital testing. Acute symptoms included abdominal pain, fever, arthralgia, and myalgia, with hypertension being the most frequent comorbidity (14.9%) and significantly associated with myalgia and arthralgia (<i>P</i> < 0.05). Colchicine was the primary treatment for 89.6% of patients, with high adherence rates (90.3%).</p><p><strong>Conclusion: </strong>Among chronic comorbidities, hypertension was associated in increasing the severity of the myalgia during attacks. The issue of misdiagnosis remains a major challenge in Jordanian clinical practice. Our findings assert the importance of future incorporation of FMF premarital testing.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 1","pages":"21-28"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11966200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
McArdle's disease presents with multiple large vessel lesions. 麦卡德尔病表现为多发性大血管病变。
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0032
Shuning Guo, Yanping Wei, Wu Di, Jing Li
{"title":"McArdle's disease presents with multiple large vessel lesions.","authors":"Shuning Guo, Yanping Wei, Wu Di, Jing Li","doi":"10.1515/rir-2024-0032","DOIUrl":"10.1515/rir-2024-0032","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"235-237"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunomodulatory effects of novel nano micelle based curcumin in rheumatoid arthritis patients: A double blind randomized clinical trial. 新型纳米胶束姜黄素对类风湿关节炎患者的免疫调节作用:一项双盲随机临床试验。
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0031
Faezeh Khamar, Mahdi Atabaki, Morteza Samadi, Marzieh Reisi, Mahnaz Sandoughi

Background and objectives: Rheumatoid arthritis (RA) is a well-known systemic autoimmune inflammatory disease. This investigation aimed to assess the effects of Sina-curcumin, a novel nano micelle-based curcumin, on immune system responses of RA patients.

Methods: This pilot study is a randomized double blinded, controlled trial. Patients who fulfilled the European League against Rheumatism-American College of Rheumatology (EULAR-ACR) criteria for RA were assigned to receive curcumin or placebo for 12 weeks. The outcomes of this study were comparison of changes in mean value of Disease Activity Score of 28 joints erythrocyte sedimentation rate (DAS28-ESR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), frequency of T helper 1 and T helper 2 cells population.

Results: From 150 RA patients who were assessed for eligibility, data from 30 patients (15 patients in each group) were analyzed. There was no significant difference between the two groups regarding age (P = 0.6441) and body mass index (BMI, P = 0.6016). Our measurement showed a statistically significant reduction in ESR (P < 0.0001), CRP (P < 0.0001) and a non-significant decrease in DAS28-ESR (P = 0.5125) in the curcumin group. Also, the Th1/Th2 ratio favorably decreased in the curcumin group. This finding was due to a significant increase in Th2 cells (P < 0.0001) and a nonsignificant decrease in Th1 cells (P = 0.1532).

Conclusion: Our trial findings revealed the immunomodulatory effects of curcumin. It could be used and recommended as adjunctive treatment for RA patients.

背景与目的:类风湿关节炎(RA)是一种众所周知的全身自身免疫性炎症性疾病。本研究旨在评估新型纳米胶束姜黄素Sina-curcumin对RA患者免疫系统反应的影响。方法:本研究采用随机、双盲、对照试验。符合欧洲抗风湿病联盟-美国风湿病学会(EULAR-ACR) RA标准的患者被分配接受姜黄素或安慰剂治疗12周。本研究的结果是比较28个关节疾病活动度评分(DAS28-ESR)、红细胞沉降率(ESR)、c反应蛋白(CRP)、辅助性T 1和辅助性T 2细胞群频率的变化。结果:从150例RA患者中,分析了30例患者(每组15例)的数据。两组在年龄(P = 0.6441)和体重指数(BMI, P = 0.6016)方面差异无统计学意义。我们的测量结果显示,姜黄素组ESR (P < 0.0001)、CRP (P < 0.0001)降低具有统计学意义,DAS28-ESR (P = 0.5125)降低无统计学意义。此外,在姜黄素组中,Th1/Th2的比值有利地降低。这一发现是由于Th2细胞的显著增加(P < 0.0001)和Th1细胞的不显著减少(P = 0.1532)。结论:姜黄素具有一定的免疫调节作用。可作为RA患者的辅助治疗。
{"title":"Immunomodulatory effects of novel nano micelle based curcumin in rheumatoid arthritis patients: A double blind randomized clinical trial.","authors":"Faezeh Khamar, Mahdi Atabaki, Morteza Samadi, Marzieh Reisi, Mahnaz Sandoughi","doi":"10.1515/rir-2024-0031","DOIUrl":"10.1515/rir-2024-0031","url":null,"abstract":"<p><strong>Background and objectives: </strong>Rheumatoid arthritis (RA) is a well-known systemic autoimmune inflammatory disease. This investigation aimed to assess the effects of Sina-curcumin, a novel nano micelle-based curcumin, on immune system responses of RA patients.</p><p><strong>Methods: </strong>This pilot study is a randomized double blinded, controlled trial. Patients who fulfilled the European League against Rheumatism-American College of Rheumatology (EULAR-ACR) criteria for RA were assigned to receive curcumin or placebo for 12 weeks. The outcomes of this study were comparison of changes in mean value of Disease Activity Score of 28 joints erythrocyte sedimentation rate (DAS28-ESR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), frequency of T helper 1 and T helper 2 cells population.</p><p><strong>Results: </strong>From 150 RA patients who were assessed for eligibility, data from 30 patients (15 patients in each group) were analyzed. There was no significant difference between the two groups regarding age (<i>P</i> = 0.6441) and body mass index (BMI, <i>P</i> = 0.6016). Our measurement showed a statistically significant reduction in ESR (<i>P</i> < 0.0001), CRP (<i>P</i> < 0.0001) and a non-significant decrease in DAS28-ESR (<i>P</i> = 0.5125) in the curcumin group. Also, the Th1/Th2 ratio favorably decreased in the curcumin group. This finding was due to a significant increase in Th2 cells (<i>P</i> < 0.0001) and a nonsignificant decrease in Th1 cells (<i>P</i> = 0.1532).</p><p><strong>Conclusion: </strong>Our trial findings revealed the immunomodulatory effects of curcumin. It could be used and recommended as adjunctive treatment for RA patients.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"227-234"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases. CD20/CD3 双特异性抗体在治疗自身免疫性疾病方面的治疗潜力。
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0029
Hongpeng Huang, Xuetao Wei

Autoimmune diseases arise from immune system dysfunction that immune cells mistakenly attack the body's own tissues, resulting in systemic disorders or localized lesions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Autoreactive B cells play a critical role in the pathogenesis of many autoimmune diseases and B cell depletion using anti-CD20 monoclonal antibody (mAb) has been shown to effectively mitigate disease progression in both preclinical and clinical studies. Recently, bispecific antibody (bsAb) targeting CD20/CD3 have demonstrated substantial clinical benefits in the treatment of various hematologic malignancies. Given their similar B cell cytotoxic mechanism, CD20/CD3 bsAb therapy may offer significant improvements in the management of many autoimmune diseases, providing a novel therapeutic option for patients. This concise review aims to summarize recent findings on CD20/CD3 bsAbs and discuss their potential in treating autoimmune diseases.

自身免疫性疾病源于免疫系统功能紊乱,免疫细胞错误地攻击人体自身组织,导致全身性疾病或局部病变,如系统性红斑狼疮(SLE)和类风湿性关节炎(RA)。自反应性 B 细胞在许多自身免疫性疾病的发病机制中起着关键作用,临床前研究和临床研究都表明,使用抗 CD20 单克隆抗体(mAb)清除 B 细胞可有效缓解疾病进展。最近,以 CD20/CD3 为靶点的双特异性抗体(bsAb)在治疗各种血液恶性肿瘤方面取得了显著的临床疗效。鉴于其相似的 B 细胞细胞毒性机制,CD20/CD3 双特异性抗体疗法可能会显著改善许多自身免疫性疾病的治疗,为患者提供一种新的治疗选择。这篇简明综述旨在总结 CD20/CD3 bsAbs 的最新研究成果,并讨论它们在治疗自身免疫性疾病方面的潜力。
{"title":"Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases.","authors":"Hongpeng Huang, Xuetao Wei","doi":"10.1515/rir-2024-0029","DOIUrl":"10.1515/rir-2024-0029","url":null,"abstract":"<p><p>Autoimmune diseases arise from immune system dysfunction that immune cells mistakenly attack the body's own tissues, resulting in systemic disorders or localized lesions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Autoreactive B cells play a critical role in the pathogenesis of many autoimmune diseases and B cell depletion using anti-CD20 monoclonal antibody (mAb) has been shown to effectively mitigate disease progression in both preclinical and clinical studies. Recently, bispecific antibody (bsAb) targeting CD20/CD3 have demonstrated substantial clinical benefits in the treatment of various hematologic malignancies. Given their similar B cell cytotoxic mechanism, CD20/CD3 bsAb therapy may offer significant improvements in the management of many autoimmune diseases, providing a novel therapeutic option for patients. This concise review aims to summarize recent findings on CD20/CD3 bsAbs and discuss their potential in treating autoimmune diseases.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"209-216"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Bouncing temporomandibular joint": Multiple temporomandibular lesions in a patient with rheumatoid arthritis. "弹跳颞下颌关节":一名类风湿性关节炎患者的多发性颞下颌关节病变。
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0033
Jun Li, Xin Gao, Haitao Dong, Jiuliang Zhao
{"title":"\"Bouncing temporomandibular joint\": Multiple temporomandibular lesions in a patient with rheumatoid arthritis.","authors":"Jun Li, Xin Gao, Haitao Dong, Jiuliang Zhao","doi":"10.1515/rir-2024-0033","DOIUrl":"10.1515/rir-2024-0033","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"238-240"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The potential for biosimilars to address unmet clinical need - Is the developed world missing out? 生物仿制药解决未满足临床需求的潜力--发达国家是否错失良机?
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0027
Whei Chuern Yeoh, Deva Situnayake, Robert J Moots
{"title":"The potential for biosimilars to address unmet clinical need - Is the developed world missing out?","authors":"Whei Chuern Yeoh, Deva Situnayake, Robert J Moots","doi":"10.1515/rir-2024-0027","DOIUrl":"10.1515/rir-2024-0027","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"186-188"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update. 中国类风湿性关节炎诊疗指南:2024年更新。
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0028
Xinping Tian, Qian Wang, Nan Jiang, Yan Zhao, Cibo Huang, Yi Liu, Huji Xu, Yaolong Chen, Lijun Wu, Jian Xu, Hongbing Li, Liangjing Lu, Jin Lin, Lie Dai, Fen Li, Zhenyu Jiang, Zhaohui Zheng, Zongwen Shuai, Shengqian Xu, Dongbao Zhao, Miaojia Zhang, Yunlin Sun, Shengyun Liu, Caifeng Li, Pingting Yang, Mengtao Li, Xiaofeng Zeng

Rheumatoid arthritis (RA) is an autoimmune disease with destructive arthritis as its main clinical manifestation, which is a major cause of disability. It is very important to formulate and update a guideline for the diagnosis and treatment of RA that adhere to international guideline development standards and can be applied to clinical practice in China. This guideline is endorsed and developed by the National Clinical Research Center for Dermatologic and Immunologic Diseases, collaborated with Rheumatologists Branch of Chinese Medical Doctor Association, Rheumatology Rehabilitation Branch of Chinese Association of Rehabilitation Medicine, Rheumatology Branch of Chinese Research Hospital Association, and Rheumatology Branch of Beijing Association of Holistic Integrative Medicine, based on grading of recommendations assessment, development and evaluation (GRADE) and reporting items for practice guidelines in healthcare (RIGHT). Evidence-based recommendation were developed for 10 clinical scenario that are most relevant to Chinese rheumatologists, aiming to improve and standardize the diagnosis and treatment of RA in China, which may finally improve the quality of life and prognosis of patients.

类风湿关节炎(RA)是一种以破坏性关节炎为主要临床表现的自身免疫性疾病,是导致残疾的主要原因。制定和更新符合国际指南制定标准、适用于中国临床实践的RA诊断和治疗指南非常重要。本指南由国家皮肤性病与免疫性疾病临床医学研究中心牵头,联合中国医师协会风湿免疫科医师分会、中国康复医学会风湿病康复分会、中国研究型医院学会风湿病学分会、北京中西医结合学会风湿病学分会,依据建议评估、发展与评价分级(GRADE)和医疗实践指南报告项目(RIGHT)制定。该研究针对与中国风湿病学家最相关的10种临床情况提出了循证建议,旨在改善和规范中国RA的诊断和治疗,最终改善患者的生活质量和预后。
{"title":"Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update.","authors":"Xinping Tian, Qian Wang, Nan Jiang, Yan Zhao, Cibo Huang, Yi Liu, Huji Xu, Yaolong Chen, Lijun Wu, Jian Xu, Hongbing Li, Liangjing Lu, Jin Lin, Lie Dai, Fen Li, Zhenyu Jiang, Zhaohui Zheng, Zongwen Shuai, Shengqian Xu, Dongbao Zhao, Miaojia Zhang, Yunlin Sun, Shengyun Liu, Caifeng Li, Pingting Yang, Mengtao Li, Xiaofeng Zeng","doi":"10.1515/rir-2024-0028","DOIUrl":"10.1515/rir-2024-0028","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is an autoimmune disease with destructive arthritis as its main clinical manifestation, which is a major cause of disability. It is very important to formulate and update a guideline for the diagnosis and treatment of RA that adhere to international guideline development standards and can be applied to clinical practice in China. This guideline is endorsed and developed by the National Clinical Research Center for Dermatologic and Immunologic Diseases, collaborated with Rheumatologists Branch of Chinese Medical Doctor Association, Rheumatology Rehabilitation Branch of Chinese Association of Rehabilitation Medicine, Rheumatology Branch of Chinese Research Hospital Association, and Rheumatology Branch of Beijing Association of Holistic Integrative Medicine, based on grading of recommendations assessment, development and evaluation (GRADE) and reporting items for practice guidelines in healthcare (RIGHT). Evidence-based recommendation were developed for 10 clinical scenario that are most relevant to Chinese rheumatologists, aiming to improve and standardize the diagnosis and treatment of RA in China, which may finally improve the quality of life and prognosis of patients.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"189-208"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing standardized diagnosis and treatment to improve the prognosis of patients with rheumatoid arthritis in China. 加强规范化诊疗,改善中国类风湿关节炎患者的预后。
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0026
Nan Jiang, Xinping Tian, Xiaofeng Zeng
{"title":"Enhancing standardized diagnosis and treatment to improve the prognosis of patients with rheumatoid arthritis in China.","authors":"Nan Jiang, Xinping Tian, Xiaofeng Zeng","doi":"10.1515/rir-2024-0026","DOIUrl":"10.1515/rir-2024-0026","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"182-185"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
14-3-3 Eta protein as a novel biomarker in early detection of uveitis in Egyptian juvenile idiopathic arthritis and rheumatoid arthritis patients: Diagnostic and prognostic value. 14-3-3 Eta蛋白在埃及青少年特发性关节炎和类风湿关节炎患者葡萄膜炎早期检测中的新生物标志物:诊断和预后价值
Pub Date : 2025-01-09 eCollection Date: 2024-12-01 DOI: 10.1515/rir-2024-0030
Dalia Salah Saif, Manar Fawzy Dawoud, Abeer Medhat, Dina Rifaat Al Sharaki, Dina Salem Fotoh

Background and objectives: Juvenile Idiopathic Arthritis (JIA) and Rheumatoid arthritis (RA) are autoimmune chronic inflammatory disorders of undetermined cause. Uveitis is one of the commonest and most dangerous extra-articular manifestations of JIA and RA presenting chronic anterior uveitis with non-specific biomarkers for its early detection. We evaluated the role of serum 14-3-3 Eta protein to assess its potential role as a novel biomarker for the early detection of uveitis in Egyptian JIA and RA patients as well as its correlation with disease activity.

Methods: A case-control study included three patient groups: group I includes 42 JIA patients, group II includes 42 RA patients, and an equal number of apparently healthy individuals matched in sex and age for each group of patients as controls, recruited from the rheumatology outpatient clinic. All participants were subjected to clinical examination, laboratory investigations with assessment of serum levels of 14-3-3 Eta protein, and ophthalmologic investigations to assess disease activity, eye affection, and its relation to 14-3-3 Eta protein level, and other disease variables among those patients.

Results: a statistically significant difference was estimated between the two patients' groups and controls regarding 14-3-3 Eta protein level. 14-3-3 Eta protein has a significant positive correlation with disease activity in JIA and RA patients. Also, RA patients with clinical uveitis had higher levels of the 14-3-3 Eta protein, while there were no significant differences among JIA patients with or without uveitis.

Conclusion: 14-3-3 Eta protein is a potential diagnostic biomarker in early detection of uveitis in RA patients, as it is higher in patients versus controls especially those with uveitis with a cut-off point 57.5, at which patients must have a thorough eye examination to receive early intervention and, to prevent complications, while it doesn't have the same role in JIA patients. 14-3-3 Eta protein is a potential diagnostic and prognostic marker for JIA and RA being correlated with disease activity.

背景和目的:幼年特发性关节炎(JIA)和类风湿关节炎(RA)是病因不明的自身免疫性慢性炎症性疾病。葡萄膜炎是JIA和RA最常见和最危险的关节外表现之一,表现为慢性前葡萄膜炎,早期检测无特异性生物标志物。我们评估了血清14-3-3 Eta蛋白的作用,以评估其作为早期检测埃及JIA和RA患者葡萄膜炎的新型生物标志物的潜在作用及其与疾病活动的相关性。方法:病例对照研究包括三组患者:I组包括42例JIA患者,II组包括42例RA患者,并从风湿病门诊招募性别和年龄相匹配的各组患者作为对照。所有患者均接受了临床检查、实验室检查(血清14-3-3 Eta蛋白水平评估)和眼科检查(疾病活动性、眼部影响及其与14-3-3 Eta蛋白水平的关系)以及其他疾病变量。结果:两组患者14-3-3 Eta蛋白水平与对照组比较,差异有统计学意义。14-3-3 Eta蛋白与JIA、RA患者疾病活动性有显著正相关。伴有临床葡萄膜炎的RA患者14-3-3 Eta蛋白水平较高,而伴有或不伴有葡萄膜炎的JIA患者14-3-3 Eta蛋白水平差异无统计学意义。结论:14-3-3 Eta蛋白是一种潜在的RA患者葡萄膜炎早期检测的诊断性生物标志物,其在RA患者中的含量高于对照组,特别是在葡萄膜炎患者中,其临界值为57.5,达到临界值时,患者必须进行彻底的眼科检查,以便进行早期干预和预防并发症,而在JIA患者中则没有相同的作用。14-3-3 Eta蛋白与疾病活动性相关,是JIA和RA的潜在诊断和预后标志物。
{"title":"14-3-3 Eta protein as a novel biomarker in early detection of uveitis in Egyptian juvenile idiopathic arthritis and rheumatoid arthritis patients: Diagnostic and prognostic value.","authors":"Dalia Salah Saif, Manar Fawzy Dawoud, Abeer Medhat, Dina Rifaat Al Sharaki, Dina Salem Fotoh","doi":"10.1515/rir-2024-0030","DOIUrl":"10.1515/rir-2024-0030","url":null,"abstract":"<p><strong>Background and objectives: </strong>Juvenile Idiopathic Arthritis (JIA) and Rheumatoid arthritis (RA) are autoimmune chronic inflammatory disorders of undetermined cause. Uveitis is one of the commonest and most dangerous extra-articular manifestations of JIA and RA presenting chronic anterior uveitis with non-specific biomarkers for its early detection. We evaluated the role of serum 14-3-3 Eta protein to assess its potential role as a novel biomarker for the early detection of uveitis in Egyptian JIA and RA patients as well as its correlation with disease activity.</p><p><strong>Methods: </strong>A case-control study included three patient groups: group I includes 42 JIA patients, group II includes 42 RA patients, and an equal number of apparently healthy individuals matched in sex and age for each group of patients as controls, recruited from the rheumatology outpatient clinic. All participants were subjected to clinical examination, laboratory investigations with assessment of serum levels of 14-3-3 Eta protein, and ophthalmologic investigations to assess disease activity, eye affection, and its relation to 14-3-3 Eta protein level, and other disease variables among those patients.</p><p><strong>Results: </strong>a statistically significant difference was estimated between the two patients' groups and controls regarding 14-3-3 Eta protein level. 14-3-3 Eta protein has a significant positive correlation with disease activity in JIA and RA patients. Also, RA patients with clinical uveitis had higher levels of the 14-3-3 Eta protein, while there were no significant differences among JIA patients with or without uveitis.</p><p><strong>Conclusion: </strong>14-3-3 Eta protein is a potential diagnostic biomarker in early detection of uveitis in RA patients, as it is higher in patients versus controls especially those with uveitis with a cut-off point 57.5, at which patients must have a thorough eye examination to receive early intervention and, to prevent complications, while it doesn'<i>t</i> have the same role in JIA patients. 14-3-3 Eta protein is a potential diagnostic and prognostic marker for JIA and RA being correlated with disease activity.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"217-226"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Rheumatology and immunology research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1